DuPont de Nemours heads into the back half of July with one of the most striking short-covering stories in specialty chemicals — short interest collapsed 63% in a single month, the stock has recovered to $139.61, and Citigroup just nudged its target higher.
The short interest story is the most dramatic thing happening on DD right now. Bears have been exiting at pace. Short interest stood near 2.9% of the free float at the start of June. By July 7 it had fallen to just 1.1%, a drop of 63% over 30 days. The absolute share count — around 4.6 million — is now less than a third of where it was in early June, when it ran above 12 million shares. That kind of exit doesn't happen quietly. Borrow conditions tell the same story: cost to borrow is negligible at 0.42%, and availability is near 985% — meaning for every share already borrowed, roughly ten more remain in the lending pool. This is one of the most comfortable lending markets in the name's recent history, and the tightest level recorded over the past year was still a loose 680% in late June. There is no squeeze dynamic here. The shorts left because they wanted to, not because they had to.
Options positioning is neutral, not directional. The put/call ratio of 0.56 is fractionally below its 20-day average of 0.58, putting the z-score near flat at -0.19. No spike in protective puts, no unusual call accumulation — the options market is simply not expressing a strong view. That's consistent with the broader picture: the stock is up 2.9% on the week but has given back 0.7% over the past month, and the short-covering tailwind is largely already in the price.
The Street is cautiously constructive. The analyst consensus leans toward buy, with a mean price target of $170.69 — implying roughly 22% upside from current levels. Citigroup lifted its target from $168 to $170 on July 2 while keeping a Buy rating, a modest incremental endorsement rather than a conviction call. The bull case rests on healthcare and water segments posting high-single-digit sales growth, driven by medical packaging and biopharma demand, alongside an innovation push that targets a 45% vitality index on new products. Bears point to delayed merger synergy realisation and persistent weakness in electronics and construction end markets, with China recovery still sluggish. Factor scores add nuance: EPS momentum is exceptional — both 30-day and 90-day readings rank in the 99th and 100th percentiles respectively — but growth and short-score metrics are weaker, with the short score rank at the 29th percentile and days-to-cover rank at just the 17th.
The insider picture is less clean. The 90-day net insider activity shows net selling of approximately $1.1 million across around 24,000 shares. CEO Lori Koch and CFO Antonella Franzen both sold in late May and early June at prices in the mid-$40s to low-$50s. Those prices — well below the current $139 — raise a consistency flag. The insider trades reported here appear to reflect a pre-split or pre-restructuring share price basis, and should not be read directly against the current quote. The trades are flagged but carry limited interpretive weight given the apparent price discrepancy.
With Q2 earnings set for August 4, the next month will test whether the healthcare and electronics recovery narrative can support a stock that has re-rated sharply from where the insiders were selling. The key tension to watch is whether EPS momentum — currently at the top of the universe — holds into the print, or whether the bear case around electronics and construction end markets reasserts itself.
See the live data behind this article on ORTEX.
Open DD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
